Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials

Aaron Denson, Nancy Burke, Georgine Wapinsky, Barbara Bertels, Tzu Hua Juan, Jae Lee, Gregory M. Springett, Jonathan R. Strosberg, Richard D. Kim, Dan M. Sullivan, Amit Mahipal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Early-phase clinical trials play a pivotal role in drug development. However, limited data are available on outcomes of gastrointestinal (GI) cancer patients enrolled in phase I clinical trials. Here, we evaluated the characteristics associated with survival in GI cancer patients participating in phase I clinical trials and attempted to validate previously established prognostic models. Materials and Methods: All consecutive patients with advanced GI tumors who participated in phase I clinical trials at our institution from January 2007 to December 2013 and received at least 1 dose of the study drug were included. Cox regression models were used to estimate multivariable-adjusted hazard ratio (HR) and 95% confidence interval. Results: In 243 study patients (median age, 62 y [range, 26 to 82 y]; 55% male), treatment included chemotherapy only (14%), targeted therapy (41%), chemotherapy + targeted therapy (42%), and others (2%) for the following disease types: pancreatic (42%), colorectal (34%), gastroesophageal (10%), hepatobiliary (13%), and others (2%). Response rate was 4%, with 38% achieving stable disease and 42% having progressive disease. Median survival was 5.8 months (range, 0.2 to 52.4 mo). Our multivariable Cox regression analyses included the following as predictors of survival: Eastern Cooperative Oncology Group performance score ≥ (HR = 1.76), prior systemic therapies ≥ (HR = 1.63), lactate dehydrogenase >618 IU/L (HR = 1.85), sodium >135 mmol/L (HR = 0.46), and white blood count >6×109/L (HR = 1.5). Our data set was consistent with previous prognostic scores. Conclusions: This is the largest study to assess clinical outcomes in this patient population. Phase I trials provide clinical benefit to patients with advanced GI malignancies and should be recommended as a treatment option in appropriate patients.

Original languageEnglish (US)
Pages (from-to)133-139
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume41
Issue number2
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Neoplasms
Gastrointestinal Neoplasms
Survival
Therapeutics
Drug Therapy
Pancreatic Diseases
L-Lactate Dehydrogenase
Proportional Hazards Models
Pharmaceutical Preparations
Sodium
Regression Analysis
Clinical Trials
Confidence Intervals
Population

Keywords

  • clinical trial
  • clinical trial
  • gastrointestinal neoplasms
  • phase I
  • survival
  • therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. / Denson, Aaron; Burke, Nancy; Wapinsky, Georgine; Bertels, Barbara; Juan, Tzu Hua; Lee, Jae; Springett, Gregory M.; Strosberg, Jonathan R.; Kim, Richard D.; Sullivan, Dan M.; Mahipal, Amit.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 41, No. 2, 01.01.2018, p. 133-139.

Research output: Contribution to journalArticle

Denson, A, Burke, N, Wapinsky, G, Bertels, B, Juan, TH, Lee, J, Springett, GM, Strosberg, JR, Kim, RD, Sullivan, DM & Mahipal, A 2018, 'Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 41, no. 2, pp. 133-139. https://doi.org/10.1097/COC.0000000000000242
Denson, Aaron ; Burke, Nancy ; Wapinsky, Georgine ; Bertels, Barbara ; Juan, Tzu Hua ; Lee, Jae ; Springett, Gregory M. ; Strosberg, Jonathan R. ; Kim, Richard D. ; Sullivan, Dan M. ; Mahipal, Amit. / Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2018 ; Vol. 41, No. 2. pp. 133-139.
@article{ed43f039e1814a77a5a921fb2a75744d,
title = "Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials",
abstract = "Objectives: Early-phase clinical trials play a pivotal role in drug development. However, limited data are available on outcomes of gastrointestinal (GI) cancer patients enrolled in phase I clinical trials. Here, we evaluated the characteristics associated with survival in GI cancer patients participating in phase I clinical trials and attempted to validate previously established prognostic models. Materials and Methods: All consecutive patients with advanced GI tumors who participated in phase I clinical trials at our institution from January 2007 to December 2013 and received at least 1 dose of the study drug were included. Cox regression models were used to estimate multivariable-adjusted hazard ratio (HR) and 95{\%} confidence interval. Results: In 243 study patients (median age, 62 y [range, 26 to 82 y]; 55{\%} male), treatment included chemotherapy only (14{\%}), targeted therapy (41{\%}), chemotherapy + targeted therapy (42{\%}), and others (2{\%}) for the following disease types: pancreatic (42{\%}), colorectal (34{\%}), gastroesophageal (10{\%}), hepatobiliary (13{\%}), and others (2{\%}). Response rate was 4{\%}, with 38{\%} achieving stable disease and 42{\%} having progressive disease. Median survival was 5.8 months (range, 0.2 to 52.4 mo). Our multivariable Cox regression analyses included the following as predictors of survival: Eastern Cooperative Oncology Group performance score ≥ (HR = 1.76), prior systemic therapies ≥ (HR = 1.63), lactate dehydrogenase >618 IU/L (HR = 1.85), sodium >135 mmol/L (HR = 0.46), and white blood count >6×109/L (HR = 1.5). Our data set was consistent with previous prognostic scores. Conclusions: This is the largest study to assess clinical outcomes in this patient population. Phase I trials provide clinical benefit to patients with advanced GI malignancies and should be recommended as a treatment option in appropriate patients.",
keywords = "clinical trial, clinical trial, gastrointestinal neoplasms, phase I, survival, therapeutics",
author = "Aaron Denson and Nancy Burke and Georgine Wapinsky and Barbara Bertels and Juan, {Tzu Hua} and Jae Lee and Springett, {Gregory M.} and Strosberg, {Jonathan R.} and Kim, {Richard D.} and Sullivan, {Dan M.} and Amit Mahipal",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/COC.0000000000000242",
language = "English (US)",
volume = "41",
pages = "133--139",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials

AU - Denson, Aaron

AU - Burke, Nancy

AU - Wapinsky, Georgine

AU - Bertels, Barbara

AU - Juan, Tzu Hua

AU - Lee, Jae

AU - Springett, Gregory M.

AU - Strosberg, Jonathan R.

AU - Kim, Richard D.

AU - Sullivan, Dan M.

AU - Mahipal, Amit

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: Early-phase clinical trials play a pivotal role in drug development. However, limited data are available on outcomes of gastrointestinal (GI) cancer patients enrolled in phase I clinical trials. Here, we evaluated the characteristics associated with survival in GI cancer patients participating in phase I clinical trials and attempted to validate previously established prognostic models. Materials and Methods: All consecutive patients with advanced GI tumors who participated in phase I clinical trials at our institution from January 2007 to December 2013 and received at least 1 dose of the study drug were included. Cox regression models were used to estimate multivariable-adjusted hazard ratio (HR) and 95% confidence interval. Results: In 243 study patients (median age, 62 y [range, 26 to 82 y]; 55% male), treatment included chemotherapy only (14%), targeted therapy (41%), chemotherapy + targeted therapy (42%), and others (2%) for the following disease types: pancreatic (42%), colorectal (34%), gastroesophageal (10%), hepatobiliary (13%), and others (2%). Response rate was 4%, with 38% achieving stable disease and 42% having progressive disease. Median survival was 5.8 months (range, 0.2 to 52.4 mo). Our multivariable Cox regression analyses included the following as predictors of survival: Eastern Cooperative Oncology Group performance score ≥ (HR = 1.76), prior systemic therapies ≥ (HR = 1.63), lactate dehydrogenase >618 IU/L (HR = 1.85), sodium >135 mmol/L (HR = 0.46), and white blood count >6×109/L (HR = 1.5). Our data set was consistent with previous prognostic scores. Conclusions: This is the largest study to assess clinical outcomes in this patient population. Phase I trials provide clinical benefit to patients with advanced GI malignancies and should be recommended as a treatment option in appropriate patients.

AB - Objectives: Early-phase clinical trials play a pivotal role in drug development. However, limited data are available on outcomes of gastrointestinal (GI) cancer patients enrolled in phase I clinical trials. Here, we evaluated the characteristics associated with survival in GI cancer patients participating in phase I clinical trials and attempted to validate previously established prognostic models. Materials and Methods: All consecutive patients with advanced GI tumors who participated in phase I clinical trials at our institution from January 2007 to December 2013 and received at least 1 dose of the study drug were included. Cox regression models were used to estimate multivariable-adjusted hazard ratio (HR) and 95% confidence interval. Results: In 243 study patients (median age, 62 y [range, 26 to 82 y]; 55% male), treatment included chemotherapy only (14%), targeted therapy (41%), chemotherapy + targeted therapy (42%), and others (2%) for the following disease types: pancreatic (42%), colorectal (34%), gastroesophageal (10%), hepatobiliary (13%), and others (2%). Response rate was 4%, with 38% achieving stable disease and 42% having progressive disease. Median survival was 5.8 months (range, 0.2 to 52.4 mo). Our multivariable Cox regression analyses included the following as predictors of survival: Eastern Cooperative Oncology Group performance score ≥ (HR = 1.76), prior systemic therapies ≥ (HR = 1.63), lactate dehydrogenase >618 IU/L (HR = 1.85), sodium >135 mmol/L (HR = 0.46), and white blood count >6×109/L (HR = 1.5). Our data set was consistent with previous prognostic scores. Conclusions: This is the largest study to assess clinical outcomes in this patient population. Phase I trials provide clinical benefit to patients with advanced GI malignancies and should be recommended as a treatment option in appropriate patients.

KW - clinical trial

KW - clinical trial

KW - gastrointestinal neoplasms

KW - phase I

KW - survival

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84946085495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946085495&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000242

DO - 10.1097/COC.0000000000000242

M3 - Article

C2 - 26523441

AN - SCOPUS:84946085495

VL - 41

SP - 133

EP - 139

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -